Cabaletta Bio, Inc. cotiza a 1.79 USD y tiene una capitalización bursátil de $303M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. The company's lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase…
| Periodo | 2026-08 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | $-0.34 | — | $-0.39 | $-0.40 |
| Estimado | $-0.34 | $-0.34 | $-0.39 | $-0.47 |
| Sorpresa | +0.0% | — | +0.0% | +14.9% |
| Métrica | CABA | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -149.8% | -40.4% | -109.4% |
| ROA | -101.7% | -32.0% | -69.7% |
| Current Ratio | 2.77 | 2.84 | -0.07 |
| Debt / Equity | — | 0.28 | — |